Holen Sie sich die Stockscreener-App
7.23
0.96%
-0.07
Vorhandelsmarkt:
7.21
-0.02
-0.28%
Schlusskurs vom Vortag:
$7.30
Offen:
$7.405
24-Stunden-Volumen:
1.08M
Relative Volume:
0.57
Marktkapitalisierung:
$571.53M
Einnahmen:
$311.71M
Nettoeinkommen (Verlust:
$163.05M
KGV:
3.6451
EPS:
1.9835
Netto-Cashflow:
$172.79M
1W Leistung:
+0.00%
1M Leistung:
+12.09%
6M Leistung:
-31.86%
1J Leistung:
-2.30%
1-Tages-Spanne:
$7.14
$7.43
1-Wochen-Bereich:
$7.14
$7.48
52-Wochen-Spanne:
$6.125
$17.43
CorMedix Inc Stock (CRMD) Company Profile
Firmenname
CorMedix Inc
Sektor
Branche
Telefon
908-517-9500
Adresse
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
Compare CRMD vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRMD
CorMedix Inc
|
7.23 | 577.07M | 311.71M | 163.05M | 172.79M | 1.9835 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-20 | Hochstufung | D. Boral Capital | Hold → Buy |
| 2025-06-30 | Herabstufung | D. Boral Capital | Buy → Hold |
| 2025-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-07 | Eingeleitet | Leerink Partners | Outperform |
| 2025-01-13 | Eingeleitet | D. Boral Capital | Buy |
| 2024-08-26 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-08-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-02-17 | Eingeleitet | Needham | Buy |
| 2020-09-29 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-09-21 | Eingeleitet | Truist | Buy |
| 2019-12-18 | Eingeleitet | B. Riley FBR | Buy |
| 2019-03-26 | Bestätigt | H.C. Wainwright | Buy |
| 2018-12-06 | Eingeleitet | ROTH Capital | Buy |
| 2017-09-25 | Bestätigt | H.C. Wainwright | Buy |
| 2017-08-10 | Bestätigt | Rodman & Renshaw | Buy |
| 2017-05-05 | Bestätigt | Rodman & Renshaw | Buy |
| 2016-11-11 | Bestätigt | FBR & Co. | Outperform |
| 2016-03-17 | Bestätigt | FBR Capital | Outperform |
| 2016-03-03 | Eingeleitet | FBR Capital | Outperform |
| 2015-11-16 | Bestätigt | ROTH Capital | Neutral |
| 2015-10-29 | Bestätigt | ROTH Capital | Neutral |
| 2015-05-06 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2014-12-08 | Bestätigt | ROTH Capital | Buy |
| 2011-10-03 | Herabstufung | Maxim Group | Buy → Hold |
Alle ansehen
CorMedix Inc Aktie (CRMD) Neueste Nachrichten
How (CRMD) Movements Inform Risk Allocation Models - Stock Traders Daily
Needham Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Do options traders know something about CorMedix stock we don't? - MSN
Airway Therapeutics Appoints Biopharma Leader Joe Todisco to Board of Directors - Bolsamania
CRMD News | CORMEDIX INC (NASDAQ:CRMD) - ChartMill
RBC Capital Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $13 - Moomoo
How The CorMedix (CRMD) Story Is Shifting With Lower Guidance And Mixed Analyst Targets - Yahoo Finance
CorMedix: A Shrinking Core And No Proven Second Engine (NASDAQ:CRMD) - Seeking Alpha
CorMedix to Participate in Needham Virtual Healthcare Conference - Sahm
CRMD Forecast, Price Target & Analyst Ratings | CORMEDIX INC (NASDAQ:CRMD) - ChartMill
RSI Check: What makes CorMedix Inc stock attractive todayWeekly Risk Summary & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Trading Systems Reacting to (CRMD) Volatility - Stock Traders Daily
CorMedix Inc. (CRMD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
CorMedix: Waiting On Phase III ReSPECT For A Further Re-Rating (Upgrade) (NASDAQ:CRMD) - Seeking Alpha
Quarterly Risk: What makes CorMedix Inc stock attractive today2026 Top Decliners & Community Shared Stock Ideas - baoquankhu1.vn
CRMD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
CRMD Stock Is The Talk Of The Town Today: What’s The Latest 2025 Revenue Forecast? - MSN
CorMedix Q4 2025 Earnings Call Transcript - MarketBeat
Market Trends: Why is CorMedix Inc stock going downQuarterly Investment Review & Community Consensus Trade Alerts - baoquankhu1.vn
CorMedix soars on increased Q2 sales guidance - MSN
Aug Update: Why is CorMedix Inc stock going downQuarterly Risk Review & Long-Term Growth Stock Strategies - baoquankhu1.vn
Vanguard disaggregates holdings; reports 0% in CorMedix (CRMD) - Stock Titan
Do Options Traders Know Something About CorMedix Stock We Don't? - Zacks Investment Research
How The CorMedix (CRMD) Investment Story Is Shifting As Analyst Targets Reset - Yahoo Finance
How Cormedix Inc. (CRMD) Affects Rotational Strategy Timing - Stock Traders Daily
Levels Update: Can CorMedix Inc outperform under higher oil pricesWeekly Stock Analysis & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Is CorMedix (CRMD) Now Offering Value After Sharp Share Price Declines? - simplywall.st
US Market Recap: What is the target price for CorMedix Inc stock2026 Stock Rankings & Daily Profit Focused Stock Screening - baoquankhu1.vn
Street Watch: Is CorMedix Inc a stock for growth or value investors2026 Momentum Check & Fast Momentum Entry Tips - baoquankhu1.vn
Aug Shorts: What makes CorMedix Inc stock attractive todayWeekly Trend Summary & Proven Capital Preservation Tips - baoquankhu1.vn
Assessing CorMedix (CRMD) Valuation After Recent Share Price Weakness And Long Term Gains - simplywall.st
CRMD Stock Price, Quote & Chart | CORMEDIX INC (NASDAQ:CRMD) - ChartMill
Why did CRMD stock tumble over 11% today? - MSN
CorMedix at Citizens Life Sciences: Strategic Expansion and Growth By Investing.com - Investing.com Canada
CRMD: REZZAYO and DefenCath drive growth, with Melinta boosting revenue and new markets targeted - TradingView
CorMedix at Leerink Conference: Strategic Evolution and Market Potential By Investing.com - Investing.com Nigeria
Cormedix Earnings Call: Peak DEFENCATH, Tough Road Ahead - TipRanks
CorMedix at Leerink Conference: Strategic Evolution and Market Potential - Investing.com
CRMD: Diversified specialty pharma advancing REZZAYO and DefenCath, with strong growth catalysts ahead - TradingView
CorMedix reports Q4 revenue of $128.6M, reaffirms 2026 guidance - Investing.com Nigeria
What is CorMedix Inc.’s book value per shareMarket Weekly Review & Fast Moving Stock Trade Plans - baoquankhu1.vn
Strength Seen in CorMedix (CRMD): Can Its 21.7% Jump Turn into More Strength? - MSN
CorMedix (CRMD) Is Down 9.4% After Reaffirming 2026 Guidance and Reporting Profit SwingWhat's Changed - simplywall.st
CorMedix Q4 2025 earnings preview - MSN
CorMedix outlines $300M–$320M revenue and $100M–$125M EBITDA targets for 2026 amid DefenCath transition and Melinta integration - MSN
CorMedix nears an 11-month low after earnings miss - MSN
CorMedix (CRMD) lags Q4 earnings estimates - MSN
CorMedix Therapeutics 2026: Portfolio Expansion, Financial Highlights, DefenCath Launch & Growth Pipeline in Specialty Pharma 1234567 - Minichart
CorMedix Strikes $300M Deal For Melinta Therapeutics, Retail Calls It A ‘Wonderful Acquisition’ - MSN
CorMedix Inc. (CRMD) Acquires Melinta Therapeutics to Expand Hospital-Focused Portfolio - MSN
Leerink cuts CorMedix stock price target on expense adjustments - Investing.com India
Finanzdaten der CorMedix Inc-Aktie (CRMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):